Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLERO-4: Everolimus + Letrozole in Advanced Breast Cancer
NCT01698918Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of everolimus in breast cancer, sponsored by Novartis. Primary endpoint: Progression-free Survival (First-line) at 2.8 years. Started Mar 2013; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01698918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01698918.